Daniel Jovanovich, MD
Cardiovascular Disease · Weirton, WVNPI 1336105949
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,263 of the $17,770 with a category attached, or 63.4%. 48 manufacturers reported payments, led by Celonova Biosciences, Inc. at 29.9% of the total. Reporting peaked in 2021 at $6,391 and has fallen 61.9% since, to $2,433 in 2025.
Across 488 payments — averaging $36.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Celonova Biosciences, Inc.$5K
- Medtronic$2K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
- Shockwave Medical, Inc$752
- Johnson & Johnson$709
- Novo Nordisk$684
- plus $7K from 42 others
What the payments were for
- Consulting fees$4,80027%
- Travel & lodging$1,4728%
- Food & beverage$11,26363%
- Education$2341%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VenaSeal$881
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$612
- FLOWTRIEVER CATHETER, S$523
- CT THROMBECTOMY SYSTEM KIT$523
- ENDURANT IIS$164
- WATCHMAN Access System$158
- HawkOne$155
- JARDIANCE$121
- Wegovy$117
- Acticor 7 VR-T DX$116
- XARELTO$115
- Abre$112
- Adapta$111
- Xience Sierra Coronary Stent System$110
How this compares
$17,770 in reported general payments places this provider in the 85th percentile of 100 cardiovascular disease providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 125 | $112,784 |
| EntrestoSacubitril/Valsartan | 80 | $83,038 |
| Repatha SureclickEvolocumab | 123 | $81,048 |
| XareltoRivaroxaban | 96 | $71,081 |
| OzempicSemaglutide | 35 | $33,522 |
| BrilintaTicagrelor | 17 | $15,938 |
| Repatha SyringeEvolocumab | 13 | $11,379 |
| Ranolazine ErRanolazine | 181 | $10,334 |
| Metoprolol Succinate | 422 | $5,211 |
| Atorvastatin Calcium | 532 | $3,913 |
| Nebivolol Hcl | 96 | $3,720 |
| Carvedilol | 203 | $1,451 |
| Amiodarone Hcl | 119 | $1,445 |
| ClopidogrelClopidogrel Bisulfate | 194 | $1,281 |
| Bumetanide | 42 | $1,172 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $321 | $112,784125 claims |
| NovartisEntresto | $340 | $83,03880 claims |
| Johnson & JohnsonXarelto | $709 | $71,08196 claims |
| Novo NordiskOzempic | $684 | $33,52235 claims |
| AstraZenecaBrilinta | $446 | $15,93817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 100 cardiovascular disease providers in West Virginia.
Other cardiovascular disease in Weirton
- Maninder BediWeirton$230K
- Sarah RinehartCharleston$303K
- Partho SenguptaMorgantown$131K
- Kofi OseiHuntington$87K
- Esam BaryunHuntington$55K
- Mohammad YousafSouth Charleston$34K
- Madhavi KadiyalaMorgantown$29K
- Rameez SayyedHuntington$21K
- David CampseyMorgantown$21K
- Casey HagerSouth Charleston$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.